top of page
  • Recruiting

NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM

Updated: Jun 15, 2022


NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Venetoclax + Kd

venetoclax

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)


A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy.


Part 4 of this study is currently enrolling.


Sponsor

AbbVie


Collaborator

Genentech, Inc; Onyx Therapeutics, Inc.


Multiple Locations

International Study

 

ClinicalTrials.gov Identifier: NCT02899052

Official Title: A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

First Posted : September 14, 2016


Click here for details on ClinicalTrials.gov

 
 

Drug: Carfilzomib

Drug: Venetoclax

Drug: Dexamethasone

 

Blood Adv;2021

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Treatment with VenKd was well tolerated and showed promising response rates in this RRMM patient population, with greater responses observed in patients with t(11;14). This trial is registered at www.clinicaltrials.gov

 

Locations

United States, Alabama

United States, Arkansas

United States, Florida

United States, Georgia

United States, Illinois

United States, Indiana

United States, Kentucky

United States, Maine

United States, Maryland

United States, Missouri

United States, North Carolina

United States, Pennsylvania

United States, Texas

United States, Utah

United States, Washington

United States, Wisconsin

Puerto Rico

Australia, New South Wales

Australia, South Australia

Australia, Tasmania

Europe

Spain

Hungary










Comments


Posts Archive
bottom of page